During human immunodeficiency virus (HIV) infection, viral reservoirs persist despite antiretroviral therapy (ART) and trigger chronic T-cell activation, which leads to immune exhaustion. T-cell exhaustion is defined by progressive loss of effector functions and occurs during chronic viral infections in mice, rhesus macaques, and humans, resulting in defective pathogen clearance [1] . Exhausted T cells express several inhibitory co-receptors, of which PD-1 is the most well-studied [2] . PD-1 is a member of the B7:CD28 superfamily that, upon binding to its ligands PD-L1 or PD-L2, functions as a coinhibitory molecule in T cell receptor (TCR) signaling [3] . During acute infections, T cells upregulate PD-1 after activation as a negative feedback mechanism [3] [4] [5] . Failure to downregulate PD-1 in the setting of chronic viral infections characterizes exhausted T cells with weak antigen-specific proliferative and cytokine responses [2] . The therapeutic potential for PD-1 inhibitors was highlighted in the chronic lymphocytic choriomeningitis virus murine infection model in which blockade of the PD-1/PD-L1 pathway restored survival and functionality of CD8 T cells [6] . Similarly, inhibition of PD-1 improved simian immunodeficiency virus-specific CD8 T-cell cytotoxic, proliferative, and cytokine responses in nonhuman primates [7, 8] . HIV-infected adults also have increased levels of PD-1 + CD8 T cells with impaired function that recover HIV-specific effector responses with blockade in vitro [9] [10] [11] .
While the role of PD-1 in HIV infection has been more thoroughly studied in CD8 T cells, its role in CD4 T-cell exhaustion has also been demonstrated. In HIV-infected (HIV + ) adults, PD-1 is upregulated on HIV-specific CD4 T cells [12, 13] and correlates with markers of disease progression [9, 12, 14, 15] . Additionally, PD-1 + CD4 T cells were recently reported to be a reservoir for latent HIV in ARTsuppressed adults [16] . Most importantly, blockade of PD-1/ PD-L1 increases HIV-specific CD4 T-cell proliferation [9, 12, 13, 15] , suggesting multiple potential therapeutic roles for immune checkpoint inhibitors in HIV infection. An important unresolved question is whether the effect of blocking the PD-1/PD-L1 pathway is limited to HIV-specific CD4 T cells, which comprise a small portion of all PD-1-expressing cells [17] , or if blockade of PD-1 also modulates function in nonspecific CD4 T cells.
HIV + children have tolerogenic immune systems with weak immune responses, leading to uncontrolled viral replication, rapid disease progression, and high mortality rates [18] [19] [20] [21] . PD-1 in these children may mediate both immune tolerance and exhaustion. HIV + children have increased PD-1 expression on CD8 T cells that correlates with immune activation [22] [23] [24] , yet the frequency, phenotype, and function of PD-1 + CD4 T cells in the pediatric population are poorly characterized. In this study, we examined CD4 T cells in a perinatally infected HIV + pediatric cohort from Mombasa, Kenya, for PD-1 expression and correlation with markers of HIV disease progression and immune activation. We also determined the functional capacity of PD-1 + CD4 T cells and effects of PD-1 blockade on CD4 + T cells. We show that frequencies of PD-1 + memory CD4 T cells are significantly elevated in HIV + children and correlate with HIV disease progression, measured by CD4 percentage, CD4:CD8 ratio, HIV plasma viremia, and T-cell activation. We further demonstrate that PD-1 + memory CD4 T cells are hypoproliferative yet preferentially secrete Th1 and Th17 cytokines compared to PD-1 -CD4 T cells and that these functional features are not reversed by in vitro PD-1 blockade.
MATERIALS AND METHODS

Study Subjects and Specimens
Ethical approval for this study was obtained from New York University and Kenyatta National Hospital/University of Nairobi. Written informed consent and age-appropriate verbal assent were obtained from all participants and/or parents. We enrolled a total of 71 perinatally infected HIV + and 40 HIVunexposed (HU) children aged 5-18 years from Bomu Hospital in Mombasa, Kenya, between 2011 and 2012. HIV + children included 38 ART-naive (ART -) and 33 HIV + children on ART for at least 6 months (ART + ). Plasma and peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Paque PLUS (GE Healthcare) density gradient centrifugation from each subject. HIV RNA was quantified on diluted plasma samples with Roche, COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0 (limit of detection 110 copies/mL). Table 1 outlines demographic and clinical characteristics of the participants.
Immune Phenotyping
PBMCs were stained with fixable viability dye (eBioscience) in phosphate-buffered saline (PBS) for 30 minutes, then stained with fluorescent-conjugated antibodies against CD3, CD4, CD8, CD45RO, CCR7, CD38, HLA-DR, and PD-1 (Supplementary Table 1 ) at 4°C for 30 minutes in PBS buffer containing 2% fetal calf serum and 0.1% sodium azide. For intracellular cytokine staining, cells were activated with phorbol 12-myristate 13-acetate (PMA; 40 ng/mL; Sigma), ionomycin (I; 500 ng/mL; Sigma), and GolgiStop (BD Biosciences) for 5 hours. Cells were stained with viability dye and surface markers CD3, CD4, CD8, CD45RO, and CCR6, then fixed, permeabilized (eBioscience kit), and stained with antibodies against interleukin (IL) 2, interferon gamma (IFN-γ), and IL-17A, then analyzed using an LSRII flow cytometer (BD Bioscience) and FlowJo software (Tree Star).
T-Cell Purification and Activation for PD-1 Sort Experiments
PBMCs were isolated from anonymous leukopaks obtained from the New York Blood Center under an institutional review board-approved protocol. CD4 + T cells were isolated from PBMCs using Dynal CD4 Positive Isolation kit (Invitrogen) and were >99% pure. CD4 + T cells were sorted into PD-1 -and PD-1 + memory cells (memory gate included CD45RO + and CR45RO-CD27 -cells) with a FACSAria cell sorter (BD Bioscience). Monocytes were isolated using Dynal CD14 Positive Isolation kit (Invitrogen) or CD14 MicroBeads (Miltenyi Biotec), then cultured with granulocyte macrophage colony-stimulating factor (50 ng/mL) and IL-4 (50 ng/mL) for 3 days to generate dendritic cells. For proliferation experiments, cells were labeled with CFSE dye (Invitrogen), activated with soluble anti-CD3 (50 ng/mL clone OKT3, ATCC) and monocyte-derived dendritic cells (1:5 ratio), cultured for 4 days, then analyzed for proliferation by flow cytometry.
Proliferation and PD-1 Blockade Experiments in HIV-Infected Children
PBMCs were labeled with CellTrace Violet Cell Proliferation kit (Invitrogen), then stimulated with soluble anti-CD3 or HIVspecific pooled Gag peptide (2 μg/mL) and CD28/CD49 (1 μg/mL). HIV Gag peptides were obtained from the National Institutes of Health AIDS Reagents program (number 12437) as a peptide set containing 15 aa length peptides that are potential T-cell determinants [25] . On day 6-7, cells were stained with viability dye and surface markers CD3 and CD4, then analyzed by flow cytometry. For blockade experiments, cells were incubated with anti-PD-1 (clone EH12.2H7, 10 μg/mL) or isotype control antibodies (mouse IgG1, κ clone MG1-45, 10 μg/mL) for 30 minutes before stimulation.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism software. For comparison of multiple groups of subjects, the Because PD-1 is mostly expressed on memory rather than naive CD4 T cells (Supplementary Figure 1A) , we determined PD-1 expression on memory CD4 T cells (CD4 T M ), defined as the sum of central (T CM , CD45RO + CCR7 + ), effector (T EM , CD45RO + CCR7 -), and RA + effector memory (EMRA) (T EMRA , CD45RO -CCR7 -) populations ( Figure 1A ). Both ART -and ART + subjects had significant increases in the percentage of PD-1 + CD4 T M compared with HU children (P < .0001 and P = .02, respectively; Figure 1A ). Similarly, PD-1 mean fluorescence intensity in CD4 T M was higher in HIV + than in HU children ( Figure 1B ). There was no correlation between age and PD-1 + CD4 T M in HU or HIV + children ( Figure 1C ). PD-1 + frequencies in memory CD8 T cells were high in ART -but not ART + children compared with HU children (Supplementary Figure  1B) . In ART -children, treatment initiation significantly lowered the frequency of PD-1 + CD4 T M , within 1 year (P = .001; Figure 1D ). However, PD-1 levels remained higher than HU at 6 and 12 months post-ART (P < .0001; Supplementary Figure  1C ). Longer durations of treatment in the ART + cohort were not associated with lower PD-1 expression in memory CD4 T cells (Supplementary Figure 1D) . We next asked which memory subset accounted for high PD-1 levels in total memory CD4 T cells. PD-1 expression was increased in T CM of ART -(P < .0001) and ART + (P = .002) children compared with HU children (Figure 2A ). ART -children also had higher PD-1 expression in T EM and T EMRA compared with HU children (Figure 2A ). HIV + children did not have similar increases in T CM , T EM , and T EMRA compared to HU children (Supplementary Figure 2A) . In each subject category, T CM and T EM comprised nearly equal proportions of the total PD-1 + CD4 T M population ( Figure 2B ). PD-1 + CD4 T M coexpressed minimal levels of other inhibitory molecules, CD160, 2B4, and TIM3, which were similar between HU and HIV + children (Supplementary Figure 2B) .
PD-1 Expression on Memory CD4 T Cells Correlates With Disease Progression in HIV-Infected Children
We determined correlations between PD-1 + CD4 T M and clinical markers of disease progression. In HIV + subjects, PD-1 + CD4 T M frequency directly correlated with HIV viral load (P = .02; Figure 3A ) in ART -children, and inversely correlated with CD4 percentage (P < .0001; Figure 3B ) and CD4:CD8 ratio (P < .0001; Figure 3C ) in HIV + children. These correlations were not present in HU (Supplementary Figure 3A) . Immune activation markers CD38 and HLA-DR predict HIV disease progression [26] . The percentage of PD-1 + CD4 T M significantly correlated with CD38 + HLA-DR + CD8 (P < .0001) and CD4 T cells (P < .0001) and CD38 + CD45RO + CD4 T cells (P = .003; Figure 3D ). There was no correlation between the PD-1 + CD4 T M and markers of immune activation in HU children (Supplementary Figure 3B) .
PD-1 + Memory CD4 T Cells Are Hypoproliferative and Predict Low Proliferative Capacity in HIV-Infected Children
We first compared proliferative potentials between PD-1 -and PD-1 + CD4 T cells isolated from anonymous leukopaks, due to limitations in blood volumes obtained from children. Sorted PD-1 + and PD-1 -memory CD4 T cells were activated through the TCR with anti-CD3, then assessed for proliferation. PD-1 + CD4 T M proliferated more than 2.5-fold less than PD-1 -CD4 T M from the same donor ( Figure 4A and 4B) . Next, we examined proliferative responses in relation to PD-1 expression on CD4 T cells in HIV + children (Supplementary Table 2 ). Total PBMCs were activated ex vivo with an antigen-independent stimulus using anti-CD3 antibody or an HIV-specific stimulus via pooled HIV Gag peptides (HIV Gag), then measured for proliferation of total CD4 T cells on day 6 ( Figure 4C ). Remarkably, higher baseline PD-1 + CD4 T M levels predicted decreased proliferative capacity within total CD4 T cells after anti-CD3 (P = .02; R 2 = 0.54) and HIV-specific stimulation (P = .04; R 2 = 0.55; Figure 4D) . Notably, the frequency of T CM or T EM in memory CD4 T cells did not predict the proliferative potential of CD4 T cells after either stimulus (Supplementary Figure 4) .
PD-1 Blockade Fails to Raise Proliferative Capacity of CD4 T Cells in HIV-Infected Children
We next evaluated whether blockade of PD-1 restored proliferative functions of CD4 T cells in HIV + children. The addition Figure 5A) . However, the percentage of proliferating CD4 T cells was similar between anti-PD-1 and isotype control antibodies after anti-CD3 ( Figure 5A and 5B) and HIV Gag ( Figure 5C and 5D) stimulation, despite high PD-1 expression. PD-1 blockade did not result in higher cell death, as the frequencies of live cells were similar between the isotype control and anti-PD-1 antibodies (Supplementary Figure 5B) .
PD-1 + Memory CD4 T Cells Produce Inflammatory Th1 and Th17 Cytokines
In PD-1 -and PD-1 + sorted memory CD4 T cells from healthy adults that were stimulated with PMA/I, the PD-1 + subset produced significantly less IL-2 and more of the inflammatory cytokine IFN-γ (P = .007 and P = .0475; Figure 6A ) compared to the PD-1 -memory CD4 T cells. Next we evaluated IL-17A production within CCR6 + PD-1 -and PD-1 + cells, as all Th17 express CCR6. PD-1 + CD45RO + CCR6 + CD4 T cells had markedly higher IL-17A levels (P = .007) compared to their PD-1 -counterpart ( Figure 6A ).
In HIV + children, we examined ex vivo cytokine production in PD-1 + and PD-1 -gated CD45RO + CD4 T cells by flow cytometry ( Figure 6B ). Activation with PMA/I did not significantly change PD-1 expression in HIV + children ( Figure 6B ), whereas it increased PD-1 levels in HU children (Supplementary Figure 6A) . PD-1 + CD45RO + CD4 + T cells from HIV + children also produced significantly less IL-2 (P = .003; Figure 6C ) and significantly more IFN-γ (P < .0001; Figure 6C ) and IL-17A (P = .0003; Supplementary Figure 6B ) compared with PD-1 -cells. CCR6 expression did not differ between PD-1 -and PD-1 + cells (Supplementary Figure 6C) , and IL-17A was >2-fold higher in PD-1 + CD45RO + CCR6 + cells compared with the PD-1 -subset (P = .0003; Figure 6C ). HU subjects also had higher IFN-γ and IL-17A production in PD-1 + CD4 T cells (Supplementary Figure  6D) . To confirm our findings in the entire HIV + cohort, we evaluated whether PD-1 expression on CD4 T M correlated with cytokine production by total CD45RO + CD4 + T cells. Indeed, PD-1 + CD4 T M frequencies correlated inversely with IL-2 (P = .008; Figure 6D ) and directly with IFN-γ and IL-17A levels in CD4 T cells (P = .005 and P = .02; Figure 6D ). In HU, there were no significant correlations between PD-1 + CD4 T M frequencies and cytokines (Supplementary Figure 6E) . PD-1 blockade with anti-PD-1 antibodies before stimulation with PMA/I or HIV Gag did not alter IFN-γ or IL-17A levels in CD45RO + CD4 T cells of HIV + children (Supplementary Figure 7) .
DISCUSSION
In this study we demonstrate that perinatally-infected HIV + children aged 5-18 years have remarkable elevations in the frequency of PD-1 + memory CD4 T cells that lower with ART, but fail to normalize. These cells are comprised of central and effector memory subsets and correlate with HIV disease progression, measured by viral load, CD4 percentage, CD4:CD8 T-cell ratio, and immune activation. In HIV + children, PD-1 + memory CD4 T cells predict both HIVspecific and -nonspecific proliferative capacity of total CD4 T cells. Despite weak proliferative potential, PD-1 + memory CD4 T cells preferentially produce Th1 and Th17 cytokines. Last, blockade of PD-1 with neutralizing antibodies failed to restore HIV-specific and -nonspecific proliferative responses or to dampen inflammatory cytokine production in HIV + children.
Our findings of increased levels of PD-1 + CD4 T cells in HIV + children that correlate with HIV disease progression are consistent with previous studies of HIV + adult subjects [9, 12, 14, 15] . The significant correlations between PD-1 + CD4 T cells and immune activation markers raise the question whether PD-1 + CD4 T cells represent exhausted T cells or a recently activated T-cell population in HIV + children. In 2 different cohorts of HIV + children from the United Kingdom [22] and Uganda [23] , PD-1 expression on CD8 T cells was positively associated with CD38 + HLA -DR + CD8 T cells; however, there are no similar pediatric reports of PD-1 + CD4 T cells. Interestingly, PD-1 expression after activation by PMA/I remained stable in HIV + children but increased in HU children, suggesting that a portion of PD-1 + memory CD4 T cells in HIV disease is activation-induced. Additional markers are necessary to discern between recently activated and exhausted PD-1 + CD4 T cells. Although subjects with recent viral illness or active coinfections were excluded from our study, the dynamics of PD-1 expression during and after acute infection remain poorly understood. Another potential explanation for the correlation between PD-1 + CD4 T cells and immune activation derives from the recent report of a viral reservoir within PD-1 + CD4 T cells [16] . Nearly half of PD-1 + CD4 T cells from HIV + children are T CM , which contains a viral reservoir in children [27, 28] . Although speculative, it is conceivable that a portion of this reservoir may intermittently replicate and trigger T-cell activation.
In our cohort of HIV + children, more than half of memory CD4 T cells were PD-1 + , yet HIV-specific cells account for only 1%-5% of the total CD4 T-cell population in chronic HIV infection [17] . Moreover, in healthy children, nearly 40% of memory CD4 T cells expressed PD-1. What functional role does PD-1 play on HIV-nonspecific T cells or in healthy hosts under physiologic conditions? Our experiments on PD-1 + and PD-1 -sorted populations from healthy adults demonstrated >2.5-fold lower proliferative potential in PD-1 + CD4 T cells after stimulation with anti-CD3 antibodies. While previous reports describe hypoproliferative PD-1 + CD4 T cells in the context of chronic viral infections [9, 15] , to our knowledge this is the first report demonstrating a marked difference in proliferative capacity between PD-1 + and PD-1 -sorted CD4 T cells in response to TCR stimulation in healthy adults. Remarkably, PD-1 + CD4 T M frequencies in HIV + children similarly predicted both HIV-specific and -nonspecific CD4 T-cell proliferative responses. Whether this muted proliferative potential derives from an exhausted or terminally differentiated state is unclear. Alternatively, regulatory T cells expressing PD-1, which we previously reported [29] , may exert suppressive functions leading to impaired proliferation.
In studies of adults, blockade of the PD-1 pathway increased HIV-specific CD4 T-cell proliferation [9, 12, 13, 15 ], yet in HIV + children, PD-1 blockade failed to raise proliferative responses to both anti-CD3 antibodies and HIV Gag peptides. Of note, most adult studies used blocking antibodies against PD-L1, whereas we used monoclonal antibodies to PD-1, as the majority of currently US Food and Drug Administrationapproved PD-1-modulating antibodies target the receptor itself. However, PD-L1 blockade in a small subset of HIV + children replicated our results with PD-1 antibodies and had no effect on proliferative capacity (data not shown). While PD-1 blockade generally yielded larger effects in untreated viremic adult subjects [13, 15] , PD-1 blockade failed to rescue proliferative capacity in both viremic and ART-suppressed children. Early studies of PD-L1 interactions with PD-1 on human CD4 T cells demonstrated that PD-L1 failed to inhibit proliferation under saturating conditions of TCR activation with anti-CD3/CD28 [30] . Due to limited blood volumes obtained from children, our experiments were optimized on adult PBMCs. It is conceivable that our ex vivo stimuli may have been too strong to overcome with blockade because optimal antigen concentrations differ between the developing pediatric and mature adult immune systems. Indeed, immune development in perinatally infected HIV + children amidst chronic antigenic stimulation may trigger irreversible T-cell exhaustion. Recently, Corneau et al characterized PD-1 + CD4 T cells in healthy and HIV + adults by large multiplex mass cytometry, and demonstrated that PD-1 + CD4 T cells were predominantly T EM and T EMRA with limited expression on T CM [31] . In HIV + children, we found a nearly equal divide between T CM and T EM in PD-1 + CD4 T cells; the functional effects of anti-PD-1 may differ between T CM and T EM subsets.
While producing significantly less IL-2 consistent with their proliferative dysfunction, PD-1 + CD4 T cells preferentially produced inflammatory Th1 and Th17 cytokines in both healthy adults and HIV + children, suggesting these cells retain robust effector properties. Porichis et al also demonstrated the PD-1 hi sorted population was the main cytokine-secreting population in chronically HIV + adults [15] . A more recent report revealed that a subset of early differentiated CD27 high CD45RA low CD127 high PD-1 + cells are highly functional with elevated cytokine production [14] . While PD-1 blockade consistently restores HIVspecific T-cell proliferation in studies of adults, results vary on whether blockade also restores cytokine production. In HIV + children, anti-PD-1 antibodies did not alter cytokine production in CD4 + T cells. Previous studies that report increased inflammatory cytokine secretion after PD-1 blockade [15, 32] measured cytokine levels in the supernatant and observed significant variability among subjects. D'Souza et al demonstrated no difference in cytokine production by HIV-specific CD4 T cells with intracellular cytokine staining assays after PD-1 blockade [12] , similar to our findings.
Interestingly, in a comparison of the gene profiles of PD-1 hi CD8 T cells in healthy vs HIV + adults, Duraiswamy et al demonstrated that the gene signature of PD-1 hi CD8 T cells in healthy subjects did not match the exhausted gene profile of PD-1 hi CD8 T cells from HIV + adults, suggesting that PD-1 hi CD8 T cells in healthy humans represent effector memory cells rather than exhausted cells [33] . In PD-1 + CD4 T cells, we found identical proliferative and cytokine functions in healthy adults and HIV + children, warranting further investigation of genetic and transcriptional signatures of PD-1 + CD4 T cells in children. Most importantly, our data demonstrate that PD-1 expression alone does not identify exhausted CD4 T cells. Rather PD-1 + CD4 T cells in children comprise a heterogeneous central and effector memory population and likely mark differentiated, exhausted, and recently activated CD4 T cells.
In summary, both treated and untreated HIV + children have significantly increased frequencies of PD-1 + memory CD4 T cells that correlate with HIV disease progression and immune activation. In healthy adults, PD-1 + CD4 T cells are hypoproliferative after TCR stimulation, and in HIV + children frequencies of these cells predict HIV-specific and -nonspecific proliferative capacity of CD4 T cells. Despite proliferative defects, PD-1 + memory CD4 T cells preferentially produce Th1 and Th17 cytokines, IFN-γ and IL-17A, respectively. Last, in HIV + children, PD-1 blockade fails to restore proliferative potential or dampen cytokine production. Together, these findings demonstrate that PD-1 + CD4 T cells are a heterogeneous subset of central and effector memory T cells with impaired proliferative capacity, yet with the potential to secrete proinflammatory cytokines. These cells are elevated in children with perinatally acquired HIV infection, correlate with disease progression, and are unresponsive to in vitro blockade. This study highlights a need for further investigation into the precise role of the PD-1 pathway in HIV + children in light of recent phase 1 clinical trials of PD-1 immune modulators in HIV + adults [34] .
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